
## **Robert Hollis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3061096/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 541-553.	1 0.784314 13.7	rgBT /Overic 75
2	Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. British Journal of Cancer, 2022, 127, 1034-1042.	6.4	14
3	Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification. Clinical Cancer Research, 2022, 28, 3546-3556.	7.0	5
4	Clear cell carcinoma of the ovary: a clinical and molecular perspective. International Journal of Gynecological Cancer, 2021, 31, 605-616.	2.5	79
5	Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2021, 27, 3201-3214.	7.0	27
6	Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. Npj Precision Oncology, 2021, 5, 47.	5.4	10
7	Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma. Cancers, 2021, 13, 5839.	3.7	8
8	Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nature Communications, 2020, 11, 4995.	12.8	70
9	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. Current Opinion in Oncology, 2020, 32, 442-450.	2.4	10
10	Infectionâ€driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells. EMBO Journal, 2020, 39, e102166.	7.8	12
11	Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. Cancers, 2020, 12, 1503.	3.7	17
12	Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. Cancers, 2020, 12, 1647.	3.7	49
13	Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1409-1420.	2.3	28
14	Abstract 4161: Integrated analysis of whole exome sequencing and hormone receptor expression data in endometrioid ovarian cancer. , 2020, , .		0
15	367â€The use of real-world evidence from the edinburgh ovarian cancer database to explore a data gap in the prima trial. , 2020, , .		0
16	Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. American Journal of Obstetrics and Gynecology, 2019, 221, 245.e1-245.e15.	1.3	22
17	Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma. Gynecologic Oncology, 2019, 155, 318-323.	1.4	18
18	High <i>EMSY</i> expression defines a BRCAâ€like subgroup of highâ€grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Cancer, 2019, 125, 2772-2781.	4.1	28

**ROBERT HOLLIS** 

#	Article	IF	CITATIONS
19	Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Gynecologic Oncology, 2019, 152, 278-285.	1.4	20
20	Molecular stratification of endometrioid ovarian carcinomas Journal of Clinical Oncology, 2019, 37, 5553-5553.	1.6	0
21	Abstract 749: Multi-layer molecular characterization of high grade serous ovarian carcinomas. Cancer Research, 2019, 79, 749-749.	0.9	1
22	Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. BMC Cancer, 2018, 18, 16.	2.6	13
23	Abstract 322: High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with superior survival and platinum sensitivity. , 2018, , .		1
24	A retrospective study of endocrine therapy in high grade serous ovarian carcinoma. Annals of Oncology, 2017, 28, v338-v339.	1.2	0
25	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. OncoTargets and Therapy, 2017, Volume 10, 2539-2551.	2.0	45
26	Genetic and molecular changes in ovarian cancer. Cancer Biology and Medicine, 2016, 13, 236-247.	3.0	82